The recent TGA approval of subcutaneous (SC) infliximab (Remsima SC) across all current infliximab indications expands the treatment options for adult patients with chronic inflammatory diseases, including inflammatory bowel disease. The SC formulation was approved by the TGA in on 12th November 2020. The manufacturer, Celltrion, has applied for reimbursement, with hopes of PBS availability ...
Introduction of sub-cutaneous infliximab (Remsima SC) expands treatment options for patients
9 Dec 2020
Sponsored by Celltrion Healthcare Australia Pty Ltd